Research programme: cancer immunotherapeutics - Aduro/Novartis

Drug Profile

Research programme: cancer immunotherapeutics - Aduro/Novartis

Alternative Names: CDNs - Aduro Biotech; LKZ 145

Latest Information Update: 28 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aduro BioTech
  • Class Antineoplastics; Small molecules
  • Mechanism of Action MPYS-protein-stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 20 Dec 2017 Aduro Biotech has patent protection for cyclic dinucleotide structures that activates Stimulator of Interferon Genes pathway in USA
  • 09 Aug 2017 Aduro Biotech receives patent allowance for cyclic dinucleotides (CDNs) in USA
  • 30 Mar 2015 CDN Technology licensed to Novartis worldwide for the treatment of Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top